Cancer is the leading cause of death in the developed countries and is also believed to be the second leading cause of death in the developing countries. Unfortunately many of the current chemotherapeutic agents are beset with limited efficacy, adverse side effects including unfavourable pharmacokinetics with some treatments known to induce secondary neoplasm and the agents are also expensive, all of which call for the discovery and development of new chemotherapeutic agents with improved profiles over existing ones. To this end some of the current research is focused on harnessing the chemotherapeutic potential of natural products. The antimalarial artemisinins have shown promising in vitro and in vivo activity against various types of cancer cells. In the current study we investigated the cytotoxicity and the underlying mechanism of action of novel derivatives of dihydroartemisinin JC3-39 and LLP271 and some tetraoxane dimers (RKA138, RKA149, RKA150, RKA151, RKA152, RKA155, RKA158 and RKA160) against HT29-AK (colon cancer) and HL60 (leukaemia) cell lines.
|Date of Award
|Omar Janneh (Supervisor) & Afthab Hussain (Supervisor)